Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, will present and host one-on-one meetings at Guggenheim’s 3rd Annual Healthcare Innovation Conference in Boston on Nov. 10, 2026. President and CEO Seth Lederman, M.D., will deliver the company presentation from 4 to 4:25 p.m. ET, with a live webcast and replay available under the News & Events tab in the Investors section of the company’s website.
The presentation matters because it gives Tonix a platform to showcase its transition into a commercial-stage company with a differentiated portfolio targeting central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved as the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure also supports its marketed acute migraine products, Zembrace® SymTouch® and Tosymra®.
Beyond its commercial products, Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. The CNS portfolio also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In immunology, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
For investors, the conference appearance is an opportunity to gauge how Tonix plans to leverage its commercial infrastructure and pipeline to drive growth. The company’s ability to execute on its Phase 2 trials and advance its immunology programs could significantly impact its long-term value proposition. Full details of the announcement are available in the press release at https://ibn.fm/f7udM, and ongoing updates can be found in the company’s newsroom at https://ibn.fm/TNXP.
The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication and editorial syndication to 5,000+ outlets, along with press release enhancement and social media distribution to millions of followers. These corporate communications solutions help companies like Tonix reach a wide audience of investors and journalists. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
